Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1

Conditions

Leukemia, Myeloid, Acute 2Myelodysplastic Syndromes 1Glioblastoma 1

Interventions

Cytarabine 146Azacitidine 99venetoclax 95Cyclophosphamide 70fludarabine 69Decitabine 63fludarabine phosphate 55Specimen Handling 35Filgrastim 35Daunorubicin 34Mitoxantrone 30Idarubicin 29Etoposide 27Injections 25Granulocyte Colony-Stimulating Factor 25Biopsy 24Busulfan 22Tacrolimus 21Clofarabine 21Mycophenolic Acid 18Melphalan 18Methotrexate 17Bortezomib 17Whole-Body Irradiation 16Stem Cell Transplantation 16Peripheral Blood Stem Cell Transplantation 16Vorinostat 15Gemtuzumab 15Lenalidomide 14decitabine and cedazuridine drug combination 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Myeloid, Acute × tandutinib × Clear all
NCT00064584 2009-03-24

Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML)

Millennium Pharmaceuticals, Inc.

Phase 1 Completed
60 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT00274248 2008-02-11

MLN518 in Combination With Standard Induction Chemo. for Treatment of Patients With Newly Diagnosed Acute Myelogenous Leukemia

Millennium Pharmaceuticals, Inc.

Phase 1 Completed
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡